First product from Daiichi Sankyo's portfolio to be introduced through Ranbaxy.
Ranbaxy Laboratories Limited (“Ranbaxy”) and Daiichi Sankyo Company Limited (“Daiichi Sankyo”) announced today that Ranbaxy will launch Olvance (Olmesartan Medoxomil, antihypertensive), which was originally discovered by Daiichi Sankyo. This follows a licensing agreement between the two companies authorizing Ranbaxy to promote and market the drug in India.
Commenting on the occasion, Mr. Malvinder Mohan Singh, Chairman, CEO and Managing Director, Ranbaxy, said, "The launch of Olvance is a historic moment in the collaboration between Ranbaxy and Daiichi Sankyo. This marks the beginning of a productive engagement that will harness the respective strengths of Daiichi Sankyo and Ranbaxy to establish a much stronger platform for Ranbaxy in India.”
Remarking on the development, Mr.Takashi Shoda, President & CEO of Daiichi Sankyo, said, “We are delighted with the introduction of Olvance in the Indian market by Ranbaxy, signifying our serious commitment to India. Olmesartan Medoxomil is a superior antihypertensive medicine that will offer an excellent therapy option to the doctors and patients in India. This marks our intent to scale up our innovative product introductions, in India, through Ranbaxy.”
Ranbaxy recognizes the responsibility of playing a pivotal role in creating awareness, understanding and acceptance of the new antihypertensive amongst the medical fraternity and other target audiences in India.
Olvance is an effective, fast acting and well tolerated antihypertensive agent that can be administered, once daily. The clinical trials of Olmesartan have shown it to be significantly more effective at reducing blood pressure, than, several other agents. Ranbaxy has a significant presence in the cardiovascular disease segment and is a pioneer and leader in Statins the cholesterol reducing agents. Introduction of Olvance will further strengthen Ranbaxy’s presence in the antihypertensive segment.
Olmesartan Medoxomil belongs to the family of Angiotensin II receptor blocker (ARB) class of anti-hypertensives and is a selective AT1 subtype angiotensin II receptor antagonist. It is available worldwide in more than 50 countries.
About Daiichi Sankyo Company, Limited
A global pharma innovator, Daiichi Sankyo Company, Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com
About Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.
